Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ibcasertib - Chipscreen Biosciences

Drug Profile

Ibcasertib - Chipscreen Biosciences

Alternative Names: Aurora B/VEGFR/PDGFR /c-Kit/CSF1R inhibitor; Chiauranib; Chiauranib - Chipscreen Biosciences; CS-2164; Ibcasertib

Latest Information Update: 02 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chipscreen Biosciences
  • Class Amides; Aniline compounds; Antineoplastics; Ethers; Naphthalenes; Quinolines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Aurora kinase B inhibitors; Macrophage colony stimulating factor receptor antagonists; Mitosis inhibitors; Platelet derived growth factor alpha receptor antagonists; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ovarian cancer; Peritoneal cancer; Small cell lung cancer
  • Phase II Graft-versus-host disease; Non-Hodgkin's lymphoma; Soft tissue sarcoma; Triple negative breast cancer
  • Phase I/II Liver cancer
  • Preclinical Pancreatic cancer
  • No development reported Solid tumours

Most Recent Events

  • 02 Jan 2024 Phase-II clinical trials in Graft-versus-host disease (PO) (Chipscreen Biosciences pipeline, January 2024)
  • 02 Jan 2024 Preclinical trials in Pancreatic cancer in China (PO) (Chipscreen Biosciences pipeline, January 2024)
  • 14 Aug 2023 Chemical structure Information added
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top